Insights into immune-related adverse events in colorectal cancer patients receiving neoadjuvant immunotherapy: findings from a multicenter registry study
{{output}}
Background: The growing use of immune checkpoint inhibitors (ICIs) in the neoadjuvant treatment of colorectal cancer (CRC) has highlighted immune-related adverse events (irAEs) as a major concern. This study aimed to investigate ... ...
